Here, we summarise the existing data on both IgE in cancer epidemiology and tumour immunosurveillance, leading to the proposal of a new hypothesis, the combinatorial hypothesis, which attempts to encapsulate the complexity of the relationship between IgE-associated immune responses with cancer; and we discuss how these insights may shape the next generation of IgE-based therapeutics. This evidence concerns the gene IGHE and neoplasm.